AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27263074 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants' comments on intervention
Number of subjects: 220
Study 27263074 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 220
Study 25532954 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 μg capsaicin
Number of subjects: 15
Study 25532954 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 μg capsaicin
Number of subjects: 15
Study 25532954 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg ASA
Number of subjects: 15
Study 25532954 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 μg capsaicin + 500 mg ASA
Number of subjects: 15
Study 25532954 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 μg capsaicin + 500 mg ASA
Number of subjects: 15
Study 22654196 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT
Number of subjects: 164
Study 22654196 — intervention group
Group type: COMPARATOR
Intervention: IRT (placebo)
Number of subjects: 164
Study 22654196 — intervention group
Group type: COMPARATOR
Intervention: TAU (treatment as usual)
Number of subjects: 164
Study 18270808 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong Healthy Women intervention
Number of subjects: 0
Study 20599292 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriene plus nicotinamide 1.4%
Number of subjects: 0
Study 20599292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20599292 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide 1.4% alone
Number of subjects: 0
Study 20599292 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriene alone
Number of subjects: 0
Study 16235180 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-valent conjugate pneumococcal vaccine (CPV); 2 doses, 4 weeks apart
Number of subjects: 109
Study 16235180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 12442196 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant load test at anaerobic lactate threshold (CTAT)
Number of subjects: 11
Study 12442196 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant load test 10% above individual threshold (CT+10%)
Number of subjects: 11
Study 9756018 — intervention group
Group type: COMPARATOR
Intervention: Systemic chemotherapy with mitomycin, mitoxanthrone and cisplatin (5 patients)
Number of subjects: 14
Study 9756018 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiac axis infusion regional chemotherapy with SpherexR microembolization (9 patients)
Number of subjects: 14
Study 8147340 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune milk (90 g daily for 10 weeks)
Number of subjects: 0
Study 8147340 — intervention group
Group type: COMPARATOR
Intervention: Normal product (control)
Number of subjects: 0
Study 3197914 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% butoconazole nitrate cream for 3 days
Number of subjects: 63
Study 3197914 — intervention group
Group type: COMPARATOR
Intervention: 1% clotrimazole cream for 6 days
Number of subjects: 63
Study 31231758 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary nitrate (NO3‐) from beetroot juice (13.4 ± 1.6 mmol NO3‐)
Number of subjects: 12
Study 31231758 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary nitrate (NO3‐) from beetroot juice
Number of subjects: 12
Study 31231758 — intervention group
Group type: COMPARATOR
Intervention: Placebo (beetroot juice devoid of NO3‐)
Number of subjects: 12
Study 29189290 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotension during surgery
Number of subjects: 9765
Study 29189290 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotension on the remaining day of surgery
Number of subjects: 9765
Study 29189290 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotension during the first four postoperative days
Number of subjects: 9765
Study 27798330 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey Protein Isolate (WPI)
Number of subjects: 60
Study 27798330 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy-Dairy Protein Blend (PB)
Number of subjects: 60
Study 27798330 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 60
Study 24225332 — intervention group
Group type: EXPERIMENTAL
Intervention: TExT-MED (2 daily text messages for 6 months)
Number of subjects: 128
Study 24225332 — intervention group
Group type: COMPARATOR
Intervention: Control group (no text messages)
Number of subjects: 128
Study 24225332 — intervention group
Group type: EXPERIMENTAL
Intervention: TExT-MED
Number of subjects: 128
Study 24225332 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 128
Study 24225332 — intervention group
Group type: EXPERIMENTAL
Intervention: TExT-MED (Spanish speakers)
Number of subjects: 128
Study 22431578 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone (C)
Number of subjects: 0
Study 22431578 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 0
Study 22431578 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 0
Study 22431578 — intervention group
Group type: COMPARATOR
Intervention: Normokalemia (potassium 3.5-5.4 mmol/L)
Number of subjects: 0
Study 22431578 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperkalemia (potassium >5.4 mmol/L)
Number of subjects: 0
Study 21094350 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary PCI in patients presenting to PCI hospitals
Number of subjects: 3340
Study 21094350 — intervention group
Group type: COMPARATOR
Intervention: Primary PCI in patients presenting to non-PCI hospitals
Number of subjects: 3340
Study 21094350 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary PCI in patients presenting with respiratory failure
Number of subjects: 3340
Study 21094350 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary PCI in patients presenting during off-work hours
Number of subjects: 3340
Study 21094350 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary PCI in patients with co-morbid conditions such as diabetes and heart failure
Number of subjects: 3340
Study 18672740 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at TH3
Number of subjects: 10
Study 18672740 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at GB43
Number of subjects: 10
Study 18672740 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture at H7
Number of subjects: 10
Study 18672740 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture at ST44
Number of subjects: 10
Study 15847970 — intervention group
Group type: EXPERIMENTAL
Intervention: Always using condoms at wave 2
Number of subjects: 416
Study 15847970 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported STIs at wave 3
Number of subjects: 416
Study 15847970 — intervention group
Group type: EXPERIMENTAL
Intervention: Unprotected anal sex at wave 3
Number of subjects: 416
Study 15847970 — intervention group
Group type: EXPERIMENTAL
Intervention: Always requesting that partners use condoms at wave 2
Number of subjects: 416
Study 15847970 — intervention group
Group type: EXPERIMENTAL
Intervention: IPV at wave 2
Number of subjects: 416
Study 12898500 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Health Treatment Court (MHTC) with Assertive Community Treatment (ACT)
Number of subjects: 235
Study 12898500 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 235
Study 11601016 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous natural porcine pulmonary surfactant (150 mg/kg)
Number of subjects: 24
Study 11601016 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal saline)
Number of subjects: 24
Study 8723849 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 1.0%
Number of subjects: 125
Study 8723849 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine 0.5%
Number of subjects: 125
Study 8723849 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine 0.75%
Number of subjects: 125
Study 8723849 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.5%
Number of subjects: 125
Study 2068825 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg of prostaglandin E2 in an intravaginal gel
Number of subjects: 37
Study 2068825 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg of prostaglandin E2 in a vaginal suppository
Number of subjects: 37
Study 2068825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 2068825 — intervention group
Group type: EXPERIMENTAL
Intervention: Both gel and suppository groups
Number of subjects: 37
Study 6140239 — intervention group
Group type: EXPERIMENTAL
Intervention: Varicocelectomy
Number of subjects: 0
Study 6140239 — intervention group
Group type: COMPARATOR
Intervention: Before varicocelectomy
Number of subjects: 0
Study 6140239 — intervention group
Group type: EXPERIMENTAL
Intervention: After varicocelectomy
Number of subjects: 0
Study 31946656 — intervention group
Group type: EXPERIMENTAL
Intervention: Social proof
Number of subjects: 143
Study 31946656 — intervention group
Group type: EXPERIMENTAL
Intervention: Tangible rewards
Number of subjects: 143
Study 31946656 — intervention group
Group type: COMPARATOR
Intervention: No extrinsic rewards (control group)
Number of subjects: 143
Study 30379128 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual phone tree
Number of subjects: 132
Study 30379128 — intervention group
Group type: EXPERIMENTAL
Intervention: Instant messaging application (IMA)
Number of subjects: 132
Study 30379128 — intervention group
Group type: COMPARATOR
Intervention: Short Message Service (SMS)
Number of subjects: 132
Study 27530630 — intervention group
Group type: EXPERIMENTAL
Intervention: One-layer duct-to-mucosa pancreaticojejunostomy
Number of subjects: 114
Study 27530630 — intervention group
Group type: COMPARATOR
Intervention: Two-layer duct-to-mucosa pancreaticojejunostomy
Number of subjects: 114
Study 24845870 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (25,000 IU retinyl palmitate per day)
Number of subjects: 31
Study 24845870 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 31
Study 24845870 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 23088844 — intervention group
Group type: EXPERIMENTAL
Intervention: Primigravidae
Number of subjects: 3591
Study 23088844 — intervention group
Group type: EXPERIMENTAL
Intervention: Multigravidae
Number of subjects: 3591
Study 20147006 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial participants
Number of subjects: 0
Study 20147006 — intervention group
Group type: COMPARATOR
Intervention: Open access users
Number of subjects: 0
Study 20147006 — intervention group
Group type: COMPARATOR
Intervention: Registered open access users
Number of subjects: 0
Study 18048991 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglitol administered in two divided doses: 25 mg just before a meal and 25 mg at 15 min after the start of a meal
Number of subjects: 15
Study 18048991 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglitol administered just before a meal (50 mg)
Number of subjects: 15
Study 18048991 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglitol administered at 15 min after the start of a meal (50 mg)
Number of subjects: 15
Study 18048991 — intervention group
Group type: EXPERIMENTAL
Intervention: All intake schedules of miglitol
Number of subjects: 15
Study 18048991 — intervention group
Group type: COMPARATOR
Intervention: Control: no miglitol
Number of subjects: 15
Study 16230541 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dose intraoperative radiotherapy with electrons (ELIOT)
Number of subjects: 355
Study 11473976 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 800 microg vaginally
Number of subjects: 10
Study 10530131 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnets
Number of subjects: 36
Study 10530131 — intervention group
Group type: EXPERIMENTAL
Intervention: Ball attachments
Number of subjects: 36
Study 10530131 — intervention group
Group type: COMPARATOR
Intervention: Bars (reference group)
Number of subjects: 36
Study 10530131 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 36
Study 8020670 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (15 mg/wk)
Number of subjects: 87
Study 8020670 — intervention group
Group type: COMPARATOR
Intervention: Colchicine
Number of subjects: 87
Study 2489230 — intervention group
Group type: EXPERIMENTAL
Intervention: CyA/EPA + DHA (fish oil)
Number of subjects: 13
Study 2489230 — intervention group
Group type: COMPARATOR
Intervention: CyA
Number of subjects: 13
Study 807869 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 23
Study 31657006 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (14,000 IU/d)
Number of subjects: 40
Study 31657006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 29620392 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral therapy (CBT)‐based guided self‐help (CBTgsh)
Number of subjects: 40
Study 29620392 — intervention group
Group type: COMPARATOR
Intervention: Waitlist
Number of subjects: 40
Study 28213632 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month weight gain prevention intervention including self-monitoring through mobile technologies and phone coaching
Number of subjects: 184
Study 28213632 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 184
Study 28213632 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month weight gain prevention intervention
Number of subjects: 184
Study 25819061 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg anagliptin twice daily
Number of subjects: 109
Study 25819061 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg anagliptin twice daily
Number of subjects: 109
Study 25819061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 23663488 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS) 100 μg, 1 spray/nostril QD for 4 weeks
Number of subjects: 319
Study 23663488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 319
Study 21852106 — intervention group
Group type: EXPERIMENTAL
Intervention: Wedge group (n=40)
Number of subjects: 80
Study 21852106 — intervention group
Group type: COMPARATOR
Intervention: Supine group (n=40)
Number of subjects: 80
Study 19081767 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum Abeta(1-40)
Number of subjects: 197
Study 19081767 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum Abeta(1-42)
Number of subjects: 197
Study 16793221 — intervention group
Group type: EXPERIMENTAL
Intervention: Interim Maintenance (IM)
Number of subjects: 319
Study 16793221 — intervention group
Group type: COMPARATOR
Intervention: Waiting List Control
Number of subjects: 319
Study 15336814 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine enriched cardioplegia and non-cardioplegic reperfusion
Number of subjects: 40
Study 15336814 — intervention group
Group type: COMPARATOR
Intervention: Control group (no L-arginine)
Number of subjects: 40
Study 11433695 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy (oral prednisolone 40 mg/d for 1 month)
Number of subjects: 33
Study 11433695 — intervention group
Group type: COMPARATOR
Intervention: Various drug treatments (including corticosteroids, colchicine, propylthiouracil, etc.)
Number of subjects: 33
Study 11433695 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal anti-TNFα antibodies
Number of subjects: 33
Study 9408666 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent assessment in RCTs of rehabilitation
Number of subjects: 0
Study 9408666 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 8459988 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg orally 3 times daily)
Number of subjects: 0
Study 8459988 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg) and dexamethasone (8 mg) given orally
Number of subjects: 0
Study 8459988 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 0
Study 3517506 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem in crystalloid potassium cardioplegia (150 micrograms/kg)
Number of subjects: 40
Study 3517506 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid potassium cardioplegia
Number of subjects: 40
Study 31092548 — intervention group
Group type: EXPERIMENTAL
Intervention: Low systemic arterial compliance (SAC) defined as ≤0.64 mL/m²
Number of subjects: 1641
Study 29758560 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter rotation during withdrawal (study group)
Number of subjects: 200
Study 29758560 — intervention group
Group type: COMPARATOR
Intervention: No catheter rotation during withdrawal (control group)
Number of subjects: 200
Study 27498918 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified bag-valve mask (BVM) with integrated internal handle
Number of subjects: 70
Study 27498918 — intervention group
Group type: COMPARATOR
Intervention: Standard unmodified bag-valve mask (BVM)
Number of subjects: 70
Study 25100366 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (100 μg daily if baseline 25[OH]D <50 nmol/L, or 50 μg daily if baseline 25[OH]D ≥50 nmol/L)
Number of subjects: 25
Study 25100366 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 22490854 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil plasma concentration <25 ng/ml
Number of subjects: 86
Study 22490854 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil plasma concentration 25-35 ng/ml
Number of subjects: 86
Study 22490854 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil plasma concentration >35 ng/ml
Number of subjects: 86
Study 19403952 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% maltodextrin solution
Number of subjects: 11
Study 19403952 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 11
Study 17166184 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid injection therapy alone
Number of subjects: 0
Study 17166184 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy alone
Number of subjects: 0
Study 17166184 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy and steroid injection therapy combined
Number of subjects: 0
Study 17166184 — intervention group
Group type: COMPARATOR
Intervention: Watch and wait policy
Number of subjects: 0
Study 15701436 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (n = 14)
Number of subjects: 26
Study 15701436 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (n = 12)
Number of subjects: 26
Study 12920254 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured, progressive, physiologically based, therapist-supervised, in-home exercise program (36 sessions of 90 minutes over 12 weeks)
Number of subjects: 100
Study 12920254 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study 10553497 — intervention group
Group type: EXPERIMENTAL
Intervention: Early onset pauciarticular juvenile chronic arthritis patients
Number of subjects: 30
Study 10553497 — intervention group
Group type: COMPARATOR
Intervention: Systemic juvenile chronic arthritis patients
Number of subjects: 30
Study 10553497 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 30
Study 8890420 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic infiltration prior to surgery
Number of subjects: 70
Study 8890420 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic infiltration at the end of surgery
Number of subjects: 70
Study 8890420 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline infiltration)
Number of subjects: 70
Study 1889273 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis with norfloxacin, polymyxin E, and amphotericin B topically, and intravenous cefotaxime 500 mg three times a day for the first five days.
Number of subjects: 56
Study 1889273 — intervention group
Group type: COMPARATOR
Intervention: Control group 1 (no antibiotic prophylaxis)
Number of subjects: 56
Study 1889273 — intervention group
Group type: COMPARATOR
Intervention: Control group 2 (no antibiotic prophylaxis)
Number of subjects: 56
Study 1889273 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis (group 3)
Number of subjects: 56
Study 6405770 — intervention group
Group type: EXPERIMENTAL
Intervention: 9.2 mg of glyceryl trinitrate (GTN) cream (acute study)
Number of subjects: 0
Study 6405770 — intervention group
Group type: EXPERIMENTAL
Intervention: 9.2 mg of glyceryl trinitrate (GTN) cream (1 h post-application)
Number of subjects: 0
Study 6405770 — intervention group
Group type: EXPERIMENTAL
Intervention: 9.2 mg of glyceryl trinitrate (GTN) cream (chronic study)
Number of subjects: 0
Study 6405770 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased dose of glyceryl trinitrate (GTN) cream (after 3 weeks)
Number of subjects: 0
Study 6405770 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (during the study)
Number of subjects: 0
Study 3800816 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group
Number of subjects: 100
Study 3800816 — intervention group
Group type: COMPARATOR
Intervention: Non-training group
Number of subjects: 100
Study 30085130 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically higher BMI (each standard deviation increase of about 4.6 kg/m2)
Number of subjects: 2115
Study 30085130 — intervention group
Group type: COMPARATOR
Intervention: Waist-to-hip ratio adjusted for BMI
Number of subjects: 2115
Study 27088193 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-wire sternal closure
Number of subjects: 200
Study 27088193 — intervention group
Group type: COMPARATOR
Intervention: Single-wire sternal closure
Number of subjects: 200
Study 25691618 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation using the Symplicity system
Number of subjects: 998
Study 23412547 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression garments (COMP)
Number of subjects: 11
Study 23412547 — intervention group
Group type: EXPERIMENTAL
Intervention: Humidification therapy (HUM)
Number of subjects: 11
Study 23412547 — intervention group
Group type: COMPARATOR
Intervention: Passive control (CON)
Number of subjects: 11
Study 23412547 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic muscle stimulation (EMS)
Number of subjects: 11
Study 21068681 — intervention group
Group type: EXPERIMENTAL
Intervention: High-speed power training at 40% of the 1-repetition maximum (1RM)
Number of subjects: 38